Effect of suplatast tosilate on antileukotriene non-responders with mild-to-moderate persistent asthma

Allergology International

Volumn 58, Issue 3, 2009, Pages 389-393

  Wada, Mariko ^a   Nagata, Satoru ^a   Kudo, Takahiro ^a   Shimizu, Toshiaki ^a   Yamashiro, Yuichiro ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antileukotriene non responders; Bronchial asthma; Children; Suplatast tosilate; Th2 cytokines

Indexed keywords

CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PRANLUKAST; SUPLATAST TOSYLATE; THEOPHYLLINE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MALE; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; OPEN STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYMPTOM; TREATMENT DURATION;

EID: 70450162956     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.08-OA-0068     Document Type: Article

References (26)

1. Global Initiative for Asthma, Updated 2005. Available at: http://www.ginasthma.org.
2. Corry DB, Kheradmand F. Control of allergic airway inflammation through immunomodulation. J Allergy Clin Immunol 2006;117:461-464 (Pubitemid 43163459)
3. Horiguchi T, Tachikawa S, Handa M et al. Effcts of suplatast tosilate on airway inflammation and airway hyperresponsiveness. J Asthma 2001;38:331-336 (Pubitemid 32643141)
4. Tamaoki J, Kondo M, Sakai N et al. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomized study. Lancet 2000; 356:273-278 (Pubitemid 30459584)
5. Carlsen KH. Pharmaceutical treatment of asthma in children. Curr Drug Targets Inflamm Allergy 2005;4:543-549
6. Leff AR. Regulation of leukotrienes in the management of asthma: biology and clinical therapy. Annu Rev Med 2001; 52:1-14.
7. Creticos PS. Treatment options for initial maintenance therapy of persistent asthma: a review of inhaled corticosteroids and leukotriene receptor antagonists. Drugs 2003;63:1-20.
8. Tasche MJ, van der Wouden JC, Uijen JH et al. Randomised placebo-controlled trial of inhaled sodium cromoglycate in 1-4-year-old children with moderate asthma. Lancet 1997;350:1060-1064
9. Nakashima M, Uematsu T. [A phase I clinical study of a Leukotriene C4, D4 and E4 receptor antagonist; ONO-1078 in healthy volunteers]. Rinnsyouiyaku 1993;9:3-29(in Japanese).
10. Kita H, Adolphson CR, Gleich GJ. Biology of eosinophils. In: Adkinson NF, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FE (eds). Middleton's Allergy: Principles and Practice. Philadelphia: Mosby, 2003;305-332
11. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006;24:147-174
12. MacPherson JC, Comhair SA, Erzurum SC et al. Eosinophils are a major source of nitric oxide-derived oxidants in severe asthma: characterization of pathways available to eosinophils for generating reactive nitrogen species. J Immunol 2001;166:5763-5772
13. Flood-Page P, Menzies-Gow A, Phipps S et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029-1036 (Pubitemid 38056318)
14. Kato Y, Fujisawa T, Nishimori H et al. Leukotriene D4 induces production of transforming growth factor-beta1 by eosinophils. Int Arch Allergy Immunol 2005;137:17-20. (Pubitemid 40868769)
15. Bandeira-Melo C, Bozza PT, Weller PF. The cellular biology of eosinophil eicosanoid formation and function. J Allergy Clin Immunol 2002;109:393-400. (Pubitemid 34234186)
16. Meager A. Cytokine regulation of cellular adhesion molecule expression in inflammation. Cytokine Growth Factor Rev 1999;10:27-39. (Pubitemid 29230850)
17. Mori A, Ogawa K, Kajiyama Y, Suko M, Kaminuma O. Th2-cell-mediated chemokine synthesis is involved in allergic airway inflammation in mice. Int Arch Allergy Immunol 2006;140:55-58 (Pubitemid 43882386)
18. Corrigan CJ, Kay AB. T cells and eosinophils in the pathogenesis of asthma. Immunol Today 1992;13:501-507
19. Park CS, Choi YS, Ki SY et al. Granulocyte macrophage colony-stimulating factor is the main cytokine enhancing survival of eosinophils in asthmatic airways. Eur Respir J 1998;12:872-878
20. Iikura Y, Imai T, Kitabayasi T. [Suplatast tosilate]. Rinnsyou to Yakubututiryou 2002;21:404-405(in Japanese).
21. Iikura Y, Akimoto K, Fukuda Y, Katsunuma T, Sugimoto H. [Effect and pharmacokinetic of IPDR-dry syrup on child asthma]. [Allergology & Immunology] 2001;8:1399-1407(in Japanese).
22. Asano K, Shiomi T, Hasegawa N et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002; 12:565-570 (Pubitemid 35177087)
23. Lima JJ, Zhang S, Grant A et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 2006;173:379-385 (Pubitemid 43228324)
24. Nakagawa T, Okayama Y, Oka T et al. Identifying predictors of response to Suplatast Tosilate among patients with moderate to severe bronchial asthma receiving inhaled steroid therapy. Allergol Int 2005;54:533-541 (Pubitemid 46206903)
25. Yoshihara S. [TH-2 type cytokine inhibitor]. [The Japanese Journal of Pediatric Allergy and Clinical Immunology] 2007;21:14-20(in Japanese).
26. Sano T, Nakamura Y, Yanagawa H et al. Add-on effects of suplatast tosilate in bronchial asthma patient treated with inhaled corticosteroids. Lung 2003;181:227-235 (Pubitemid 37176054)